Unknown
PHASE2
INTERVENTIONAL
NCT02935023
Carbon Ion Radiotherapy in Treating Patients Undergoing Systemic Therapy for Oligo-metastatic Prostate Cancer
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The goal of this clinical study is to determine impact of carbon ion radiotherapy (CIRT) treatment in combination with systemic therapy for oligo-metastatic prostate cancer. The primary objective: to determine disease biochemical progression-free survival in man with oligo-metastatic (M1a/b) prostate cancer undergoing systemic therapy with definitive radiotherapy of the primary tumor. The secondary objective: to determine local control, overall survival and quality of life in men with oligo-metastatic prostate cancer undergoing carbon ion radiotherapy
Interventions
Name:
CIRT with systemic therapy arm
Type:
RADIATION
Description:
carbon ion radiotherapy to the prostate(59.2GyE/16Fx to prostate and seminal vesicle) Systemic therapy:Hormonal therapy (LHRH agonist and/or antiandrogens) or chemotherapy
Primary Outcomes
Measure:
Time to PSA relapse
TimeFrame:
From the start of systemic therapy, a median of 2 years
Description:
Trial Information
NCT ID
NCT02935023
Status
Unknown
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Shanghai Proton and Heavy Ion Center
Last Updated
December 15, 2025